<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563537</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC05-PC / SLA</org_study_id>
    <nct_id>NCT00563537</nct_id>
  </id_info>
  <brief_title>Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PET imaging of activated microglia offers a tool of investigation of a range of brain
      diseases where neuroinflammation is a component.

      Amyotrophic lateral sclerosis is the most frequent motoneuronal disease in adult.

      This study was designed to explore the feasibility of molecular imaging modality by Positron
      Emission Tomography using 18F-X as an in vivo marker of activated microglia for the
      assessment of neuroinflammation in amyotrophic lateral sclerosis.

      PET may help in the diagnosis of the disease and, further, may allow assessment of the
      efficacy of antiinflammatory treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      18F-X PET will be carried out requiring arterial sampling in 2 patients suffering from ALS
      and 2 normal subjects in order to evaluate the 18F-X quantification.

      Then simplified PET using 18F-X will be carried out in 13 patients and 13 normal subjects.

      Binding potential maps showing specific binding of 18f-X will be generated for each subject.

      Regional binding potential values will be calculated for anatomically defined regions of
      interest after coregistration to and special transformation into the subject's own MRI.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative in vivo-imaging of 18F-X microglial binding site as a mesure of disease activity followed up by non invasive quantification of patients using imaging modality.</measure>
    <time_frame>Inclusion period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evidence of the localisation of benzodiazepine binding site related to microglial activation in ALS</measure>
    <time_frame>inclusion period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of the difference of microglial localisation and activation between bulbar and spinal form of amyotrophic lateral sclerosis</measure>
    <time_frame>inclusion period</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Bulbar Disease</condition>
  <condition>Spinal Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18F-X PET Scan imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>18F-X PET SCAN</intervention_name>
    <description>18F-X PET Scan : Injection of 7.8 mSv for 370 MBq of dose (0.021 mSv / MBq)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  suffering from probable or definite form of amyotrophic lateral sclerosis according to
             El Escorial criteria. Spinal or bulbar site of the disease.

          -  Information and signature of the written consent form

          -  French Social Security registration

        Exclusion Criteria:

          -  family history of ALS

          -  Riluzole treatment before the first PETscan.

          -  Psychiatric disorders

          -  Evolution of the disease older than 18 months

          -  Antiinflammatory or antibiotic treatment in the last month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis GUILLOTEAU, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Service de médecine nucléaire in Vitro - CHRU TOURS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe CORCIA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Neurologie - CHRU Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine ROUSSEL</last_name>
    <phone>(33) 2.47.47. 97.89</phone>
    <email>roussel@med.univ-tours.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Médecine Nucléaire et Ultrasons - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <state>Region Centre</state>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Caroline PRUNIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien PRALINE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Kassiou M, Meikle SR, Banati RB. Ligands for peripheral benzodiazepine binding sites in glial cells. Brain Res Brain Res Rev. 2005 Apr;48(2):207-10. Epub 2005 Jan 22. Review.</citation>
    <PMID>15850659</PMID>
  </reference>
  <reference>
    <citation>Banati RB. Visualising microglial activation in vivo. Glia. 2002 Nov;40(2):206-17. Review.</citation>
    <PMID>12379908</PMID>
  </reference>
  <results_reference>
    <citation>Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, Price G, Wegner F, Giovannoni G, Miller DH, Perkin GD, Smith T, Hewson AK, Bydder G, Kreutzberg GW, Jones T, Cuzner ML, Myers R. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain. 2000 Nov;123 ( Pt 11):2321-37.</citation>
    <PMID>11050032</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang MR, Kumata K, Maeda J, Yanamoto K, Hatori A, Okada M, Higuchi M, Obayashi S, Suhara T, Suzuki K. 11C-AC-5216: a novel PET ligand for peripheral benzodiazepine receptors in the primate brain. J Nucl Med. 2007 Nov;48(11):1853-61.</citation>
    <PMID>17978354</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang MR, Maeda J, Ogawa M, Noguchi J, Ito T, Yoshida Y, Okauchi T, Obayashi S, Suhara T, Suzuki K. Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F]fluoroethyl-5-methoxybenzyl)acetamide, for pet imaging of peripheral benzodiazepine receptor in primate brain. J Med Chem. 2004 Apr 22;47(9):2228-35.</citation>
    <PMID>15084121</PMID>
  </results_reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2007</study_first_submitted>
  <study_first_submitted_qc>November 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <last_update_submitted>March 18, 2010</last_update_submitted>
  <last_update_submitted_qc>March 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2010</last_update_posted>
  <responsible_party>
    <organization>University Hospital, Tours</organization>
  </responsible_party>
  <keyword>neurology</keyword>
  <keyword>sclerosis</keyword>
  <keyword>imaging</keyword>
  <keyword>tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Spinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

